Department of Ophthalmology, Sifa University, Izmir 35100, Turkey.
Medicina (Kaunas). 2018 Apr 16;54(2):16. doi: 10.3390/medicina54020016.
Corneal neovascularization (CNV) is a vision-threatening condition arising from various corneal diseases. The aim of this study is to compare the effectiveness of bevacizumab and interferon alpha-2a (IFNα-2a) treatment on corneal neovascularization.
Twenty-four Wistar albino rats were used in this study. After cauterization of the cornea with a silver nitrate applicator stick, the control group received 0.1 mL saline solution, the second group received 0.1 mL IFNα-2a (IFNα-2a, 6 million international units [MIU]/0.5 mL), and the third group received 2.5 mg bevacizumab by subconjunctival injection. An additional injection was administered to each group on the fourth day. After one week, the corneal neovascularization rate and the longest neovascular sprout length were determined.
The neovascularization rate (saline 0.65 ± 0.05; IFNα-2a 0.62 ± 0.07; bevacizumab 0.42 ± 0.11) with bevacizumab was significantly lower, more than those with IFNα-2a and saline (p < 0.001 and p < 0.001). The longest neovascular sprout length (saline, 4.00 ± 0.6 mm; IFNα-2a, 3.63 ± 0.52 mm; bevacizumab, 2.81 ± 0.65 mm) with bevacizumab was significantly shorter than those with saline and IFNα-2a (p = 0.001 and p = 0.012).
Subconjunctival IFNα-2a has limited efficacy in the treatment of corneal neovascularization.
角膜新生血管（CNV）是一种由各种角膜疾病引起的威胁视力的疾病。本研究旨在比较贝伐单抗和干扰素α-2a（IFNα-2a）治疗角膜新生血管的效果。
本研究使用了 24 只 Wistar 白化大鼠。用硝酸银棒烧灼角膜后，对照组给予 0.1 mL 生理盐水，第二组给予 0.1 mL IFNα-2a（IFNα-2a，600 万国际单位[MIU]/0.5 mL），第三组给予 2.5 mg 贝伐单抗球结膜下注射。每组在第四天再给予一次注射。一周后，确定角膜新生血管化率和最长新生血管芽长度。
贝伐单抗组的新生血管化率（生理盐水 0.65±0.05；IFNα-2a 0.62±0.07；贝伐单抗 0.42±0.11）明显低于 IFNα-2a 组和生理盐水组（p<0.001 和 p<0.001）。贝伐单抗组最长新生血管芽长度（生理盐水 4.00±0.6 mm；IFNα-2a 3.63±0.52 mm；贝伐单抗 2.81±0.65 mm）明显短于 IFNα-2a 组和生理盐水组（p=0.001 和 p=0.012）。
球结膜下 IFNα-2a 治疗角膜新生血管化的疗效有限。
